Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
暂无分享,去创建一个
Hiroaki Kazui | Minoru Yasuda | Etsuro Mori | Yoko Nakano | E. Mori | H. Kazui | M. Hashimoto | Y. Nakano | Mamoru Hashimoto | Keiji Matsumoto | M. Yasuda | Keiji Matsumoto
[1] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[2] S. Shimohama,et al. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. , 1997, Annals of neurology.
[3] S. Wisniewski,et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[4] Dirk Deleu,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. , 2001, Neurology.
[5] B. Gordon,et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.
[6] R. Sperling,et al. Donepezil therapy in clinical practice: a randomized crossover study. , 2000, Archives of neurology.
[7] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[8] C. Jack,et al. MRI‐Based Hippocampal Volume Measurements in Epilepsy , 1994, Epilepsia.
[9] Gregory McCarthy,et al. Quantitative magnetic resonance imaging in temporal lobe epilepsy: Relationship to neuropathology and neuropsychological function , 1992, Annals of neurology.
[10] H Matsuda,et al. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] E. Mori,et al. Medial temporal structures relate to memory impairment in Alzheimer’s disease: an MRI volumetric study , 1997, Journal of neurology, neurosurgery, and psychiatry.
[12] B. Winblad,et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD , 2001, Neurology.
[13] R. Mohs,et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.
[14] A. Kertesz. Long-term donepezil treatment in patients with Alzheimer’s disease , 2004 .
[15] M. Farlow,et al. A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease , 2000, European Neurology.
[16] C. Jack,et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.
[17] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[18] J. Hardy,et al. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.
[19] K. Davis,et al. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. , 1983, Psychopharmacology bulletin.
[20] C. Jack,et al. MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.
[21] J. Raftery,et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.
[22] D. Kirschner,et al. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.
[23] C. Cotman,et al. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[24] B. Wolf,et al. Muscarinic Regulation of Alzheimer's Disease Amyloid Precursor Protein Secretion and Amyloid β-Protein Production in Human Neuronal NT2N Cells (*) , 1995, The Journal of Biological Chemistry.
[25] Hiroaki Kazui,et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E ε4 allele , 2002 .
[26] H. Wiśniewski,et al. Pathology of Alzheimer's disease. , 1991, The Psychiatric clinics of North America.
[27] K. Davis,et al. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Nordberg,et al. Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25‐35) in rat PC12 cells , 1998, Neuroreport.
[29] Xin Yu,et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.
[30] S. Shimohama,et al. Nicotinic receptor stimulation protects neurons against β‐amyloid toxicity , 1997 .
[31] S Lehéricy,et al. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. , 1994, AJNR. American journal of neuroradiology.
[32] E. Mori,et al. Clinical Diagnosis of Dementia with Lewy Bodies in a Japanese Dementia Registry , 1999, Dementia and Geriatric Cognitive Disorders.
[33] R. Mohs,et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.
[34] PhilipR. Wenham,et al. Apolipoprotein E genotyping by one-stage PCR , 1991, The Lancet.
[35] Hiroaki Kazui,et al. Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer’s disease , 2001, Neurology.
[36] H. Soininen,et al. Volumes of hippocampus, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: Correlation with memory functions , 1995, Journal of neural transmission. Parkinson's disease and dementia section.
[37] Rachelle S. Doody,et al. DONEPEZIL STUDY GROUP. A 24-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL OF DONEPEZIL IN PATIENTS WITH ALZHEIMER'S DIS-EASE , 1998 .